Biosynex Stock

Biosynex Net Margin

The Net Profit Margin of Biosynex (ALBIO.PA) as of Aug 14, 2026 is -42.83 %. In the previous year, Net Profit Margin was -39.93 % — a change of 7.28% (lower).

Net Margin

-42.83 %

YoY

7.28%

Last updated:

Net Profit Margin of Biosynex is 2026 -42.83 % . Net Profit Margin of Biosynex was 2025 -39.93 % . It decreases by 7.28% lower compared to the previous year.

Biosynex's net margin stands at -42.8%, down from 20.4% several years earlier.

Access this data via the Eulerpool API

Biosynex Stock analysis

What does Biosynex do? The company Biosynex SA was founded in 2005 in Strasbourg, France. The company is a manufacturer and distributor of diagnostic test kits used for the rapid and accurate diagnosis of various infectious diseases and other health conditions. Biosynex SA has established itself as a leading player in the global health market in recent years. The business model of Biosynex SA includes the design, manufacture, and distribution of various medical diagnostic tests that are capable of quickly and efficiently detecting pathogens and other health conditions. The company offers a wide range of medical test kits that can be used for the diagnosis of HIV/AIDS, hepatitis C, syphilis, rapid pregnancy tests, menopause, bleeding during pregnancy, vitamin D deficiency, and many other health conditions. The main focus of Biosynex SA is on developing test kits that are easy to use and provide accurate and reliable results. With its technological know-how and collaboration with leading experts in the field of medical diagnostics, Biosynex SA has taken a leading position in the development and marketing of medical diagnostic test kits. By collaborating with doctors, hospitals, and clinics globally, Biosynex SA has successfully expanded its business. Biosynex SA has various business areas specifically focused on the marketing and distribution of medical diagnostic tests. The most well-known areas include gynecology, infectious diseases, and pediatrics. Biosynex SA also has a strong presence in the global market, including Asia, Europe, Africa, and America. One of the most well-known products of Biosynex SA is the HIV self-test called Autotest VIH®, which is available in many European countries and North America. The test kit is CE marked and approved by leading health authorities such as the WHO and the EU. The product is an important tool in reducing the spread of HIV infections and allowing people to make a confidential diagnosis of HIV/AIDS in a private setting. In the field of gynecology, Biosynex SA offers various products such as the Unistick® pregnancy test, Unistick® ovulation test, and Unistick® menopause test kit. These products enable women to easily and efficiently diagnose pregnancy, ovulation, and menopause. The test kits are easy to use, can be used at home, and provide results within minutes. In summary, Biosynex SA has earned its leading position in the global market due to its focus on innovative technology and high-quality product range. The company has made a significant contribution to improving healthcare worldwide with its expertise and commitment to diagnosing health conditions. Biosynex SA will continue to expand its business in the future to support even more people worldwide and further improve the quality of healthcare. Biosynex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biosynex stock

Net Profit Margin of Biosynex is -42.83 % in 2026.

Net Profit Margin of Biosynex changed from -39.93 % to -42.83 %, representing a 7.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Biosynex since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Biosynex with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Biosynex

All Key Metrics — Biosynex